T
his is the third of three articles dealing with the International Diabetes Federation meeting, which was held in Paris, 24 -29 August 2003 .
Paul Valensi (Bobigny, France) discussed approaches to silent myocardial ischemia in persons with diabetes. Addressing the question of whether it is in fact advisable to detect cardiovascular disease (CVD) in persons without history of myocardial infarction or angina, he noted the poor prognosis of persons with diabetes, whose risk of myocardial infarction in the absence of CVD is similar to that of persons without diabetes and with a prior myocardial infarction. Those having evidence of CVD are at particularly increased risk, with half dying within 8 years (1) . One-year mortality after thrombolysis is increased by half in persons with diabetes, and survival of persons without diabetes who have had a second myocardial infarction is similar to that of those with diabetes after an initial event (2) . The prevalence at autopsy of high grade and multilevel coronary atherosclerosis in diabetic individuals without clinical coronary artery disease (CAD) is similar to that of persons without diabetes with clinical CAD, both for males and for females (3) . In a French multicenter study of 417 asymptomatic diabetic persons with at least two additional risk factors undergoing thallium scintigraphy with exercise or dipyridamole, 162 had positive nuclear study, and of 70 having angiography, 39 were found to have evidence of CAD, a positive predictive value of only 56%. Other studies suggest that approximately one-third of asymptomatic persons with diabetes have a positive screening test, but that only approximately one-third of these have positive results on angiography, suggesting poor correlation between functional and morphological abnormality. Alternatively, Valensi suggested, scintigraphy may actually be more sensitive than angiography to the presence of CAD, noting that there certainly is evidence that an abnormal study is associated with poor prognosis. There is, however, at this time no evidence that assessment of asymptomatic patients improves outcome, although a large study would be needed to demonstrate this. He suggested that screening of persons with risk factors was justified, although acknowledging that with current guidelines the majority of persons with diabetes have evidence of additional risk factors. In the French study, 13% of patients had a major CVD event over mean 37-month follow-up, with those having positive scintigraphy studies having a two-to threefold increase in risk. Patients with events were ϳ4 years older, more likely to be males, and had higher triglyceride and lower HDL cholesterol, but it was difficult to demonstrate a threshold level. A cost-effective strategy would be to study persons with diabetes duration of at least 5 years having two or more risk factors, or diabetic nephropathy, or peripheral arterial insufficiency (4) .
Cardiac autonomic neuropathy (CAN) is associated with poor prognosis, with a recent metaanalysis showing a 3.5-fold increase in mortality in persons with two separate positive tests for CAN (5) . The adverse effect of CAN is particularly manifest in persons with evidence of silent ischemia. Age is another important marker; a cutoff of 60 years leads to a higher positive predictive value of positive angiography and a higher rate of major CVD events, which occur in ϳ33 vs. 13% of those above versus below this age. Positive family history and left ventricular hypertrophy are additional important risk markers.
T ) studied an animal model of sulfonylurea inhibition of cardioprotection from ischemic preconditioning. With versus without a 5-min period of coronary artery occlusion 10 min before a 30-min occlusion, followed by 2 h of reperfusion, the preceding brief occlusion decreased the extent of infarct, with glyburide but not glipizide inhibiting the benefit of the ischemic preconditioning, adding to a large body of evidence that only the former sulfonylurea may exhibit this adverse effect. A. Stirban et al. (abstract 31) reported that ingestion of an advanced glycation end product-rich beverage not containing either carbohydrate or lipid reduced brachial artery flow-mediated dilation in 44 persons with diabetes, suggesting an adverse effect on endothelial function.
Inflammation
John Yudkin (London, U.K.) discussed the relationship between inflammation and CVD. There is a strong relationship between CRP and mortality in the general population as well as in persons with diabetes. The acute inflammatory response involves a cellular infiltrate, resulting in the production of CRP, which is a major circulating protein. Microinflamation, as shown by elevations of CRP to 3-5 mg/l, may represent inflammation within the vessel wall, a process that is associated with atherosclerosis. However, arterial and venous neutrophil myeloperoxidase levels only show a fall across arterial beds in persons with unstable angina, suggesting that other than in this special case the major determinant of inflammation in diabetes is not arterial inflammation. The insulin resistance syndrome (IRS) is associated with elevations of CRP and phospholipase A2, with other features including hyperinsulinemia as well as elevations in proinsulin, plasminogen activator inhibitor 1, triglyceride, smalldense LDL particles, and free fatty acid (FFA), as well as albuminuria and endothelial dysfunction, leading Yudkin to explain that "the new IRS is enormous and includes low-grade inflammation." Acute phase markers such as tumor necrosis factor (TNF)-␣, interleukin (IL)-6, and CRP correlate well with the measures of insulin resistance. Markers of endothelial activation are also correlated, so that the acute phase markers may underlie the association of endothelial damage with the IRS. CRP is produced in the liver in response to a number of signals, particularly IL-6. Measuring antibodies to heliobacter pylori, Chlamydia, and cytomegalovirus, there was only weak association, while much stronger association was present with markers of insulin resistance and with central obesity. Adipose tissue venous levels of cytokines show particular increase in IL-6, which is strongly associated with markers of insulin resistance, although there is no increase in TNF-␣ in adipose venous drainage. The adipocyte, then, appears to be responsible for up to one-third of levels of inflammatory cytokines, particularly in obese persons. Yudkin speculated that proinflammatory cytokines may be at the center of the processes underlying the IRS, having effects on proinsulin-insulin conversion, on endothelium in various tissues, on coagulation, and on multiple additional abnormalities of the IRS and potentially underlying the association between insulin resistance and vascular disease. Central obesity, physical stress, myocardial infarction, infection, reduced physical activity, and perhaps advanced glycation end products may all stimulate proinflammatory cytokine production. Another important fat-derived molecule is adiponectin, acting as a negative regulator Perspectives on the News of insulin resistance. Clearly, then, weight reduction would appear to be an important treatment for the inflammatory state. Rates of obesity are increasing in the developing and developed world. The measurement of BMI itself may not suffice in distinguishing risk across populations, as the degree of adiposity varies with different ethnic groups. Weight reduction leads to decreases IL-6, IL-18, and CRP levels and to an increase in adiponectin. In high doses, aspirin affects nitric oxide (NO)-dependent endothelial vasodilation, not via cyclooxygenase, while low-dose aspirin is not effective in decreasing CRP levels, although being of benefit in decreasing CVD events. Indeed, in the Physicians Health Study, aspirin was effective in people with high but not with low CRP. It did not lower CRP per se but rather was a marker of persons who would benefit from treatment. There have been similar findings for statin treatment, with lovastatin showing particular benefit in persons with low LDL if CRP was high but not in those with low levels. TZDs do appear to lower CRP, with Yudkin showing a study comparing persons randomized to 0, 4, or 8 mg rosiglitazone daily, with active treatment decreasing matrix metalloproteinase and CRP levels, although not associated with change in IL-6. The Leuven intensive care unit insulin therapy study showed marked decrease in mortality, sepsis, renal insufficiency, and peripheral neuropathy, with significant decreases in CRP levels, suggesting that this may be a factor. M. Oxidant stress Antonio Ceriello (Naples, Italy) discussed the association between oxidative stress and development of complications in diabetes. The classical scheme has been of insulin resistance leading to hyperglycemia, initially most marked postprandially, in persons developing diabetes. Macrovascular disease is, however, present throughout this process, leading Ceriello to speculate that oxidative phenomena may provide an explanatory link. Overnutrition and decreasing physical activity are occurring worldwide and appear to cause cellular overload with glucose and FFA. When glucose passes through tissues it is transformed to energy in the mitochondria with production of free radicals. "This is the key pathway," Ceriello said, but only the first event. Free radicals are accompanied by an increase in inflammatory markers, ultimately leading to decreased metabolic insulin response in a variety of tissues and to endothelial dysfunction. In addition, glucose and FFA may in part induce ␤-cell dysfunction via oxidative stress. Thus, Ceriello suggested that oxidative stress may be central, leading to diabetogenic effects on the ␤-cell, on endothelium, and on insulin target tisssues. New antioxidant agents may allow approaches to treatment, both decreasing CVD and decreasing the development of diabetes. He concluded by recalling Ovid's evocative "Gutta cavat lapidem, non vi sed saepe cadendo." ("A drop carves the rock, not by force but by persistence.") Eva Lonn (Hamilton, ON, Canada) reviewed evidence for benefit of antiinflammatory treatment, agreeing that oxidative stress is a major mechanism of atherogenesis, acting in part by causing endothelial dysfunction.
Vitamin E is thought to be the most potent naturally occurring antioxidant, with vitamin C a water soluble antioxidant that regenerates vitamin E. Vitamin E has been shown to decrease platelet adhesion and aggregation and smooth muscle proliferation. Extensive epidemiologic studies suggest that CVD risk is greater in regions with lower antioxidant intakes, particularly of antioxidant vitamins. Some studies show inverse relationship between ␤-carotene intake and risk, particularly in male smokers. There is an inverse relationship between ␣-tocopherol intake and CVD risk in men and women. For vitamin C, the data are less consistent, with the National Health and Nutrition Examination Survey suggesting an association between vitamin C and decreased mortality. The U.S. Nurses' Health Study and Physicians Health Study and several Finnish studies show decreased CVD risk with vitamin E supplementation of at least 100 IU/day. There are, however, inconsistencies in the epidemiologic data. Some studies have only shown relationship to vitamin E intake from food rather than from supplements, although there is potential bias in that persons taking vitamins or following a diet higher in vitamins may differ in other ways from those not following these approaches.
A number of randomized controlled trials have been carried out. There is some evidence of improved endothelial function with vitamin E supplementation, although the beneficial effect may be lost with prolonged supplementation. Morbidity and mortality trials are limited by the duration of observation of reported being ϳ4 -6 years, while benefit may require longer periods. However, the studies that have been carried out have in general not shown benefit, including the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study (520 persons) (6), the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SE-CURE) (732 persons) (7), the vitamin E Atherosclerosis Prevention Study (VEAPS) (320 persons) (8), the de Waart study (180 persons) (9), the Fang study (40 persons) (10), the HDL Atherosclerosis Treatment Study (HATS) (160 persons) (11) , and the Women's Angiographic Vitamin and Estrogen (WAVE) Trial (423 persons) (12) . Furthermore, in the HATS trial the benefit of simvastatin plus niacin was diminished with addition of the antioxidants, in the WAVE trial there was similarly suggestion of loss of benefit, and in the SECURE trial the measurement of carotid intima-media thickness showed "absolutely no effect of vitamin E." The SPACE trial from Israel of 196 persons with end-stage renal disease showed a decrease in vascular events with vitamin E treatment (800 IU/day) (13) . A variety of other large trials, however, failed to show effect or actually suggested increased mortality with ␤-carotene in the ␣-tocopherol and ␤-carotene (ATBC) trial (25,563 men) (14) , the ␤-Carotene and Retinol Efficacy Trial (CARET) (18,314 persons) (15) , and in studies of vitamin E Bloomgarden DIABETES CARE, VOLUME 27, NUMBER 7, JULY 2004 including the ATBC trial, the Cambridge Heart Antioxidant Study (CHAOS) (2002 persons) (16), the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI) (11, 324 persons; this trial did, interestingly, show benefit of dietary supplementation with n-3 polyunsaturated fatty acids) (17), the Heart Outcomes Prevention Evaluation (HOPE) Study (9,541 persons) (18) , and the Heart Protection Study (HPS) (20,536 persons) (19) . Fewer studies are available with vitamin C, Lonn noted, although there was small and insignificant increase in risk in three small studies. Studies particularly addressing persons with diabetes show no benefit in mortality, other vascular outcomes, or microvascular outcomes. The Koupio Study of 944 men aged 42-60 does suggest decreased risk of diabetes with vitamin E. In the HOPE study, baseline inflammatory markers were associated with increased risk of development of diabetes, but there was no difference in the risk of developing diabetes.
The larger Nutrition Intervention Trial in Linxian, China, in 29,584 adults showed some evidence of benefit of selenium (20) . Other antioxidants, including superoxide dismutase, probucol, and probucol-like agents, may prove to be useful, and there is some evidence that ACE inhibitors may have antioxidant effects. At present, however, Lonn concluded that there is no benefit of antioxidant vitamin supplement in persons with or without diabetes, although noting that "the available evidence does not, however, refute the oxidative hypothesis of atherosclerosis."
In a vitamin-related sidelight, a number of authors presented studies of type 1 diabetes prevention with vitamin D. A. Homocysteine Ellen Hoogeveen (Leiden, Netherlands) discussed homocysteine as a CVD risk factor. Type 2 diabetes, she stated, is associated with increased CVD risk, which cannot be fully explained by classic risk factors. New risk factors include increased homocysteine, which is present in between 5 and 30% of the normal population, modifiable by folate administration, and associated with venous thrombosis, neural tube and other pregnancy defects, and accelerated atherosclerosis. Levels of 5-15 mol/l are normal, 15-30 mol/l mildly increased, 30 -100 mol/l intermediate, and Ͼ100 mol/l severely elevated. McCully initially reported severe hyperhomocysteinemia due to inborn metabolic errors to be associated with accelerated atherosclerosis (21) , with subsequent realization that 50% of untreated patients have a major CVD event before age 30. Studies in 1985 showed that lowering homocysteine with B-vitamin treatment decreases this risk (22) . Homocysteine is an amino acid derived from dietary methionine by demethylation, an intermediate metabolite at the intersection of the methionine synthase (B12 dependent and folate requiring) and cystathionine ␤ synthase (B6-dependent) pathways. The latter transsulfuration pathway is confined to the liver and kidneys. Three quarters of homocysteine in plasma is protein bound, mainly to albumin. The ability to measure total homocysteine has allowed recognition of the importance of levels measurable in the general population. Median homocysteine levels are 9 -11 mol/ in women and 10 -12 mol/l in men, with a mild increase present in 4 -12% of women and somewhat more frequently in men and an age-related increase in levels. There is inverse relationship with plasma folate and B12 and a less strong relationship to vitamin B6. Two-thirds of persons with elevated homocysteine have low folate or, less commonly, B12 or B6. Folate treatment for 6 weeks shows lowers homocysteine by ϳ25%, with similar effect with administration of folate in doses of 0.5, 1, and 5 mg daily. B12 decreases homocysteine by ϳ7%, and B6 has no effect in the general population. The methylenetetrahydrofolate reductase 677C-T mutation is associated with 30 -50% decrease in enzyme activity and a 30% higher homocysteine level. This mutation is present in 5-15% of the population and can be treated with folate supplementation. There is also an inverse relationship between homocysteine and the creatinine clearance. Postulated adverse vascular effects of homocysteine include increased reactive oxygen leading to endothelial dysfunction, proliferation of vascular smooth muscle, and lipid peroxidation. Homocysteine levels exceeding 18 mol/l are associated with a threefold increase in risk of microalbuminuria compared with levels Ͻ10, with each 5-mol/l increase associated with a 28% higher relative risk of albuminuria. Survival of persons with CVD is inversely related to plasma homocysteine. In a study of 587 persons with angiographically confirmed CAD, there was a 4.5-fold increase in risk among persons with homocysteine Ͼ20 mol/l (23). Similar persons have been reported for persons with and without diabetes with renal disease (24) . Hoogeveen reported data from the Hoorn study, similarly showing increased mortality risk with increased homocysteine, with mildly increased homocysteine a twofold stronger risk factor for persons with than for those without diabetes. Independent mortality effects of both homocysteine and diabetes have been reported in other studies (25) . Meta-analysis shows that, after adjustment for risk factors, a 25% decrease in homocysteine, which can be achieved with folate supplementation of 0.5 mg daily, is associated with decreased CHD and stroke by 11 and 19%, respectively (26) . In a Swiss study of 205 patients undergoing successful angioplasty randomized to folate versus placebo, restenosis occurred in 20% vs. 38% of patients, suggesting benefit (27) .
G.T. Russo et al. (abstract 1118) studied 383 persons with type 2 diabetes and 100 healthy control subjects, showing that age, creatinine, vitamin B12 and folate status, and the methylenetetrahydrofolate reductas C677T polymorphism are the main determinants of homocysteine plasma levels in type 2 diabetic subjects, as in nondiabetic individuals, while diabetes duration, HbA 1c , and treatment (with insulin, sulfonylureas, or metformin) and the presence of diabetes complications did not affect homocysteine plasma concentrations. G. Cieslik et al. (abstract 1944) found higher homocysteine levels in obese nondiabetic than in lean persons and higher levels in males than in females, without effect of troglitazone 400 mg daily or of rosiglitazone 4 mg daily for 6 weeks in 9 and 11 obese persons, respectively. had hypertension, 15% dyslipidemia, 20% diabetes, and 61% overweight, with 40% having three or more components of the metabolic syndrome. They noted that cancer diagnosis occurred 5-9 years after that of diabetes or metabolic syndrome, suggesting this to be a particularly important group for screening. D.S. Papagogias et al. (abstract 675) reported that 21 persons with asymptomatic pancreatic cancer were found among referrals for newonset diabetes to their center over the past decade. These patients typically had greater degrees of hyperglycemia and had CA-19-9 Ͼ 300 IU/ml. (Their normal is Ͻ37 IU/ml, but a comparison group having newly diagnosed diabetes without pancreatic cancer had levels Ͻ50.) J. Damiano et al. (abstract 2029) reported their experience with routine pancreatic imaging by either sonography or computer tomography scan in 115 persons Ͼ50 years of age with acute severe hyperglycemia, reporting that six patients had pancreatic adenocarcinomas, one a benign pancreatic tumor, one a metastatic cancer with pancreatic extension, one a neuroendocrine tumor, one pancreatitis, one non-Hogkin's lymphoma, two ovarian cancer, and one renal carcinoma.
